Zou Yanmei, Xiong Hua, Xiong Huihua, Lu Tao, Zhu Feng, Luo Zhiyong, Yuan Xianglin, Wang Yihua
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Tumour Biol. 2015 Apr;36(4):2929-36. doi: 10.1007/s13277-014-2923-8. Epub 2014 Dec 11.
Mushroom Huaier has become a focus of interest in the treatment of hepatocellular carcinoma (HCC). Presently, we isolated and purified one polysaccharide from this mushroom. This study aimed to investigate the effects of SP1 on tumor growth and metastasis in a HCC xenograft model and explore its possible mechanism of action. Our results showed that SP1 not only significantly inhibited the proliferation of SMMC-7721 cells in vitro at the concentration ranging from 0 to 800 μg/ml but also suppressed the HCC tumor growth and metastatic nodules to the lung in SMMC-7721-bearing mice by oral administration at three doses of 30, 60, and 120 mg/kg. Concomitantly, immunohistochemistry analysis of tumor tissues identified that SP1 administration at three doses significantly inhibited the in vivo cancer cell proliferation and microvessel density (MVD) formation, evidenced by a low proliferating cell nuclear antigen (PCNA) and CD34 expression, but increased the percentage of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells. Keeping in line with this observation, SP1 treatment decreased serum matrix metalloproteinase (MMP) 2 and vascular endothelial growth factor (VEGF) levels, downregulated the protein expression of hypoxia-inducible factor (HIF)-1alpha, VEGF, MMP2, bcl-2, N-cadherin, signal transducer and activator of transcription 3 (STAT3), and metadherin (MTDH), and upregulated bax and NE-cadherin protein expression in tumor tissues. Taken together, our data suggest that SP1 appears to be a promising chemopreventive agent for the tumorigenesis and metastasis in patients with HCC, especially at advanced stages.
槐耳菌已成为肝细胞癌(HCC)治疗领域的研究热点。目前,我们从这种蘑菇中分离并纯化出一种多糖。本研究旨在探讨SP1对HCC异种移植模型中肿瘤生长和转移的影响,并探究其可能的作用机制。我们的结果表明,SP1不仅在0至800μg/ml的浓度范围内显著抑制体外SMMC - 7721细胞的增殖,还通过以30、60和120mg/kg三种剂量口服给药,抑制了荷SMMC - 7721小鼠体内HCC肿瘤的生长以及肺转移结节的形成。同时,对肿瘤组织进行免疫组化分析发现,三种剂量的SP1给药均显著抑制体内癌细胞增殖和微血管密度(MVD)形成,增殖细胞核抗原(PCNA)和CD34表达降低可证明这一点,但末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)阳性细胞的百分比增加。与此观察结果一致,SP1治疗降低了血清基质金属蛋白酶(MMP)2和血管内皮生长因子(VEGF)水平,下调了肿瘤组织中缺氧诱导因子(HIF)-1α、VEGF、MMP2、bcl - 2、N - 钙黏蛋白、信号转导子和转录激活子3(STAT3)以及黏附素(MTDH)的蛋白表达,并上调了bax和NE - 钙黏蛋白的蛋白表达。综上所述,我们的数据表明,SP1似乎是一种有前景的化学预防剂,可用于预防HCC患者尤其是晚期患者的肿瘤发生和转移。